Saturday, August 8, 2026

FTC sues Amare Global Holdings over health claims for dietary supplements

The Federal Trade Commission has filed suit against Amare Global Holdings Inc., alleging false health benefit claims about its dietary
X / Twitter
LinkedIn
Print

The Federal Trade Commission sued Amare Global Holdings Inc. and three of its principals on June 2 for allegedly misrepresenting that its dietary supplements could treat or cure conditions such as depression, anxiety, and ADHD in both children and adults. The complaint also accuses the company of misleading seller recruits about potential earnings as ‘brand partners.’

Amare markets products including Kids Happy Juice, Kids Mood+, and the Happy Juice Product Pack. The FTC alleges that Shawn Talbott, Patrick Hintze, and David Chung are responsible for making false, misleading, and unsubstantiated claims about these products. Talbott and Hintze are already subject to previous FTC orders prohibiting them from making such claims.

“Amare’s claims were not only deceptive but dangerous, since it was aware that some brand partners were taking advantage of parents looking for products to help their children, who suffer from serious conditions like depression and anxiety and need proven treatments,” said Christopher Mufarrige, Director of the FTC’s Bureau of Consumer Protection. “Companies must make truthful marketing claims and abide by FTC orders, and those that fail to do so will be held accountable by the FTC.”

According to the complaint, Amare distributes its supplements through a network of salespeople participating in a multilevel marketing scheme as ‘brand partners,’ who amplify unsubstantiated health benefit claims on social media platforms such as Instagram, TikTok, YouTube, and Facebook. These include assertions that the products can improve mental health conditions in children and adults or are ‘scientifically backed’ or clinically proven.

The FTC further alleges violations of the FTC Act by claiming without substantiation that Amare’s products can lower cortisol levels; raise serotonin, dopamine or GABA; or cure mental health disorders like depression or ADHD. Additionally, Amare is accused of making deceptive income promises to prospective sellers regarding earning potential regardless of prior experience.

The Commission authorized staff to file the complaint with a 2-0 vote in U.S. District Court for Central District of California. The staff attorneys involved are Christopher Erickson, Abbey Wallace, and Kimberly Nelson from the Bureau of Consumer Protection.

Filed Under

Share This Story

X / Twitter
LinkedIn
Email
Print

Advertisement

300 × 250

Related

Daily Dispatch

The morning briefing on federal government — delivered to your inbox before 7 AM.

Advertisement

300 × 120

More from Defense

HUD, Census Report June 2026 New Home Sales Data

The Department of Housing and Urban Development and the U.S. Census Bureau released new residential sales data for June on July 24. The figures provide the most recent snapshot of...

VA Launches Trial of Ozempic Drug for Veteran Alcohol Use Disorder

The Department of Veterans Affairs launched a clinical trial of semaglutide as a potential treatment for alcohol use disorder in veterans on July 30. The condition affects an estimated 400,000...

EPA Proposes to Ease New Hampshire Ozone Compliance Burden

The Environmental Protection Agency proposed to withdraw New Hampshire from the Ozone Transport Region and separately ease the state’s vehicle inspection and maintenance program mandate on Aug. 6. The actions...